Drummond M - Search Results

1

Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.

Cook JR, Yin D, Alemao E, Drummond M. Cook JR, et al. Among authors: drummond m. Pharmacoeconomics. 2004;22 Suppl 3:37-48. doi: 10.2165/00019053-200422003-00005. Pharmacoeconomics. 2004. PMID: 15669152

2

Selection of end points in economic evaluations of coronary-heart-disease interventions.

Drummond MF, Heyse J, Cook J, McGuire A. Drummond MF, et al. Med Decis Making. 1993 Jul-Sep;13(3):184-90. doi: 10.1177/0272989X9301300303. Med Decis Making. 1993. PMID: 8412546

3

Assessing the appropriateness of combining economic data from multinational clinical trials.

Cook JR, Drummond M, Glick H, Heyse JF. Cook JR, et al. Among authors: drummond m. Stat Med. 2003 Jun 30;22(12):1955-76. doi: 10.1002/sim.1389. Stat Med. 2003. PMID: 12802815

4

Economic endpoints in clinical trials.

Cook J, Drummond M, Heyse JF. Cook J, et al. Among authors: drummond m. Stat Methods Med Res. 2004 Apr;13(2):157-76. doi: 10.1191/0962280204sm359ra. Stat Methods Med Res. 2004. PMID: 15068259

5

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Drummond M, et al. Value Health. 2009 Jun;12(4):409-18. doi: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12. Value Health. 2009. PMID: 19900249 Free article.

6

Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.

Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, Waters DD, Drummond M, Weinstein MC. Rosen VM, et al. Among authors: drummond m. Pharmacoeconomics. 2010;28(1):47-60. doi: 10.2165/11531440-000000000-00000. Pharmacoeconomics. 2010. PMID: 20014876

7

What do international pharmacoeconomic guidelines say about economic data transferability?

Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, Reed SD, Sculpher M, Severens JL; ISPOR Good Research Practices Economic Data Transferability Task Force. Barbieri M, et al. Among authors: drummond m. Value Health. 2010 Dec;13(8):1028-37. doi: 10.1111/j.1524-4733.2010.00771.x. Value Health. 2010. PMID: 20667054 Free article.

8

Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Ikegami N, Drummond M, Fukuhara S, Nishimura S, Torrance GW, Schubert F. Ikegami N, et al. Among authors: drummond m. Pharmacoeconomics. 2002;20 Suppl 2:1-7. doi: 10.2165/00019053-200220002-00001. Pharmacoeconomics. 2002. PMID: 12238943 Review.

9

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Barbieri M, Wong JB, Drummond M. Barbieri M, et al. Among authors: drummond m. Pharmacoeconomics. 2005;23(6):607-18. doi: 10.2165/00019053-200523060-00007. Pharmacoeconomics. 2005. PMID: 15960556

10

Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations.

Hughes DA, Tilson L, Drummond M. Hughes DA, et al. Among authors: drummond m. Pharmacoeconomics. 2009;27(8):635-43. doi: 10.2165/10899570-000000000-00000. Pharmacoeconomics. 2009. PMID: 19712007 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,166 results

Search Page

Filters